The concern of generic challenges has repeatedly loomed above copyright’s famous drug, PDE5 Inhibitor, sparking questions about the future of related pharmaceutical portfolios. While initial periods saw substantial returns, the exclusivity end has allowed the way for discounted substitutes, potentially lowering revenue and creating a significant